PVEN Press Ventures Inc (CE)

Press Ventures Inc. (OTCQB:PVEN) ("Press Ventures" or the "Company"), is pleased to announce that it has secured the global sales and marketing rights to a patented all-natural essential oil disinfectant and diffusing system that has been shown to effectively combat and eradicate infection from molds, fungus, and airborne viruses. Due to the increased frequency, potential, and public awareness of global pandemics, virus outbreaks, and food bacteria deaths, the demand for a proven all-natural biosafety solution has never been greater. The Company believes that it now has the best natural and safe solution available to combat these global outbreaks which threaten the world's population. Press Ventures expects to immediately move forward to exploit new business opportunities worldwide with the patented all-natural cedar oil disinfectant and diffusing system technologies. "We're very optimistic about the timing and the global scale of the opportunity here and felt that the public market was the best venue to finance and launch this exciting biosafety technology," said Edward Denkiewicz, CEO of Press Ventures. "We are now in a unique position to build a fantastic business based on this technology and to help people all over the world combat the spread of harmful bacteria, molds, fungus, and airborne viruses in their own homes, businesses, and schools." The global market for virus and bacteria security is estimated to be valued at over $50 billion annually. North America constitutes the largest share of the infection control market, followed by Europe, Asia, and South America. The overall rise in number of chronic diseases, pandemic disease outbreaks (such as H1N1), and an aging population has enhanced the growth and importance of this market. Cost-containment issues have also led to the growth of the services sterilization market. The lack of government funds, however, has led to a decrease in innovation and enhancement of current technologies used for sterilization and disinfection. The Asian market is expected to display particularly favorable growth in the coming years primarily due to rise in health awareness, growth of aging population, increase in number of surgical procedures, and growth in per capita income. Additional information regarding the Company's biosafety technology business and the licensing agreement can be found in a "Super 8-K" filed with the Securities and Exchange Commission on their EDGAR system (www.sec.gov). Notice Regarding Forward-Looking Statements This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, demand for natural biosafety solutions, exploitation of business opportunities, strategic business goals, size of the global market for virus and bacteria security, rise in diseases, growth of the services sterilization market, growth of the Asian market, our business and product development plans and projections, and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

CONTACT: Investor Relations Contact:
         1-888-709-1550
         IR@kingstonir.net